OrganiGram (OGI -1.03%) leaped into the spotlight recently on the news that British American Tobacco (BTI -0.24%) bought a big stake in the Canadian marijuana company.
In this video captured from Motley Fool Live on March 12, veteran Fool contributor Eric Volkman and healthcare and cannabis bureau chief Corinne Cardina discuss whether OrganiGram is a now a buy in the wake of that deal.
Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 15 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.
Simply click here to get the full story now.
Corrine Cardina: Do you have any thoughts on OrganiGram as a stock? Will this push it into buy territory for you, is it a good sign for OrganiGram investors?
Eric Volkman: They're getting better. What I like about OrganiGram is that they're not trying to attack the market like some of these bigger companies, like Canopy Growth (CGC -0.66%), like Tilray (TLRY) before the Aphria (APHA) deal. OrganiGram, still has a fairly modest footprint.
Are they a buy? I think they're worth looking at, among Canadian stocks. They are limited by that market. Let's remember, Canadian stocks, the problem is that weed is still not legalized [in the U.S.] or even decriminalized. They are so limited in what they can do in this country, it's almost nothing. And if you look at Canada, it's got what is almost one-tenth of the population of the U.S. It's not a huge country, and it's vast.
So you have a smaller market, first of all. Secondly, you have the challenges of that bigness. Also on top of that, you're dealing with provinces and in some cases municipalities that have all kinds of different licensing regimes and regulations. Some are quick to license -- Alberta, for example, was pretty effective in its rollout. Some are slow, unfortunately. One of the slow ones is Ontario, which just happens to be the biggest province. On top of that, you have other challenges such as the black market. The black market is still fairly prevalent in Canada.
Overall, I would say the Canadian market is probably going to remain challenging. I wouldn't generally be bullish on Canadian stocks, but if you had to rate OrganiGram among those, I think it's probably one of the more promising ones. And it's small, it's not going to suddenly collapse from its own weight.
